Status:
COMPLETED
Low Versus High Dose Magnesium Sulfate in the Early Management of Rapid Atrial Fibrillation
Lead Sponsor:
University of Monastir
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Objective: To assess the efficacy and the safety of high (9g) and low dose (4.5g) of MgS in the immediate treatment of rapid AF.
Detailed Description
Introduction: Atrial fibrillation (AF) is a potentially life-threatening cardiac arrhythmia and a frequent chief complaint in emergency departments (ED). It is an important concern for a substantial ...
Eligibility Criteria
Inclusion
- All patients presenting to ED with rapid AF (Heart rate \>120 bpm).
Exclusion
- Unstable hemodynamic state.
- Renal insufficiency (creatinemia\> 180 µmol/l).
- Allergy to MgS.
Key Trial Info
Start Date :
November 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT00965874
Start Date
November 1 2009
End Date
August 1 2014
Last Update
April 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Monastir
Monastir, Monstir, Tunisia, 5000